Abstract |
Glucocorticoids (GCs) were discovered in the 1940s and were administered for the first time to patients with rheumatoid arthritis in 1948. However, side effects were subsequently reported. In the last 7 decades, the mechanisms of action for both therapeutic properties and side effects have been elucidated. Mechanisms for minimizing side effects were also developed. GCs are the most frequently used class of drugs in the treatment of rheumatoid arthritis because of their efficacy in relieving symptoms and their low cost. A review of clinical applications, side effects, and drug interactions is presented.
|
Authors | Joana Fonseca Ferreira, Alaa Abdelkhalik Ahmed Mohamed, Paul Emery |
Journal | Rheumatic diseases clinics of North America
(Rheum Dis Clin North Am)
Vol. 42
Issue 1
Pg. 33-46, vii
(Feb 2016)
ISSN: 1558-3163 [Electronic] United States |
PMID | 26611549
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2016 Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Administration, Oral
- Arthritis, Rheumatoid
(drug therapy)
- Atherosclerosis
(chemically induced)
- Cardiovascular Diseases
(chemically induced)
- Diabetes Mellitus, Type 2
(chemically induced)
- Dose-Response Relationship, Drug
- Drug Interactions
- Glucocorticoids
(administration & dosage)
- Humans
- Infections
(chemically induced)
- Injections, Intra-Articular
- Injections, Intramuscular
- Maintenance Chemotherapy
- Osteonecrosis
(chemically induced)
- Osteoporosis
(chemically induced)
- Osteoporotic Fractures
(chemically induced)
- Weight Gain
|